Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EQ)

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Business Wire 12 days ago

Equillium to Present at the Stifel Healthcare Conference

Business Wire 12 days ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Business Wire 13 days ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Business Wire October 31, 2024

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Business Wire October 7, 2024

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Business Wire September 10, 2024

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 4, 2024

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Business Wire August 28, 2024

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Business Wire August 8, 2024
View More News ››

Opinion & Analysis (NDAQ:EQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EQ)

Equillium Announces Positive Topline Data from Phase 2 Study

News; $EQ Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata20% of all subjects that completed the...
whytestocks - June 4, 2024

Strong Hold!

HUGE news! New partnership with Ono, a leading Japanese pharmaceutical company to further itolizumab!! the potential of itolizumab is...
Shanemorg58 - December 6, 2022

RE:RE:Bang zoom

JohnTool321 - August 5, 2022

RE:RE:Bang zoom

SusanBolland - July 11, 2022

RE:RE:Bang zoom

Lisagerrard17 - July 8, 2022

RE:RE:Bang zoom

Those T cells can be tricky.
Joe455 - May 30, 2022
View more Bullboard ››

Pinnacle Silver & Gold Corp

Pinnacle Silver & Gold Corp

Pinnacle is currently focused on district-scale exploration for precious metals in the prolific Red Lake District of ...
View More »